Vanguard Group’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Vanguard Group’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$420K	Buy	+18,247	New	+$317K	﹤0.01%	3976
2024 Q3	–	Sell	-8,848	Closed	-$105K	–	4356
2024 Q2	$105K	Hold	8,848	–	–	﹤0.01%	4229
2024 Q1	$173K	Hold	8,848	–	–	﹤0.01%	4195
2023 Q4	$159K	Buy	8,848 +156	+2%	+$2.4K	﹤0.01%	4251
2023 Q3	$156K	Buy	8,692 +2,854	+49%	+$112K	﹤0.01%	4291
2023 Q2	$368K	Buy	5,838 +3,192	+121%	+$174K	﹤0.01%	4197
2023 Q1	$132K	Buy	2,646 +1,063	+67%	+$56.1K	﹤0.01%	4372
2022 Q4	$45.5K	Buy	1,583 +214	+16%	+$8.88K	﹤0.01%	4454
2022 Q3	$65K	Hold	1,369	–	–	﹤0.01%	4522
2022 Q2	$59K	Buy	1,369 +341	+33%	+$15.6K	﹤0.01%	4576
2022 Q1	$57K	Hold	1,028	–	–	﹤0.01%	4614
2021 Q4	$78K	Sell	1,028 -82	-7%	-$6.44K	﹤0.01%	4618
2021 Q3	$99K	Buy	1,110 +128	+13%	+$13.7K	﹤0.01%	4529
2021 Q2	$124K	Buy	+982	New	+$134K	﹤0.01%	4398

Other funds holding DMRA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jain Global New York $24.2B AUM 34.82% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group's DMRA Position: Q4 2025 in Review

Vanguard Group opened a new position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q4 2025: 18,247 shares worth $420K. The stake represents ﹤0.01% of the portfolio and ranks #3976 among its holdings. This is a return to the name: Vanguard Group previously reported a position in DMRA as recently as Q2 2024.

Vanguard Group first reported a position in DMRA in Q2 2021 and has held it in 14 quarters since. 18 funds tracked by Wall St. Rank hold DMRA as of Q4 2025.

Vanguard Group held 18,247 shares of Damora Therapeutics, Inc. Ordinary Shares worth $420K as of Q4 2025.
Damora Therapeutics, Inc. Ordinary Shares was a new Vanguard Group position in Q4 2025.
Damora Therapeutics, Inc. Ordinary Shares made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3976 holding.
Vanguard Group first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q2 2021 and has held it in 14 quarters since.
18 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.